SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that it will be presenting a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting, taking place in Rotterdam, September 21-24, 2023. The presentation will include data from its lead program, VAL-083, for the treatment of recurrent glioblastoma. 

Details of the presentation are as follows: 

• Topic Section: Clinical neuro-oncology
• Presentation Time: Saturday, September 23, 2023 – 5:15 p.m. to 6:45 p.m. CEST
• Title: Phase 2 Study of VAL-083 and Radiotherapy in Newly Diagnosed MGMT-unmethylated GBM: Case Study Reports
• Abstract/ Poster Number: P11.41.B
• Presenter: Dr. Zong-ping Chen, Professor & Chairman of Department of Neurosurgery/Neuro-oncology of Sun Yat-sen University Cancer Center, Guangzhou, China & Dr. John Langlands, Kintara Therapeutics Inc, San Diego, CA

Abstracts will be published on the website of Neuro-Oncology on September 7, 2023.

Kintara recently hosted an event featuring key opinion leaders Patrick Y. Wen, M.D. (Harvard Medical School) and John de Groot, M.D. (UCSF Health) discussing the current treatment landscape for patients suffering from GBM along with Kintara's potential treatment solution with VAL-083. More information about VAL-083 and its potential as a first-in-class small molecule chemotherapeutic for glioblastoma (GBM), can be found on the replay of that event here. 

ABOUT KINTARA

Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for glioblastoma (GBM) and REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).

VAL-083 is a 'first-in-class', small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the Global Coalition for Adaptive Research registrational Phase 2/3 clinical trial titled Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study to support the development and commercialization of VAL-083 in GBM.

Kintara also has a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications.

For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and LinkedIn.

SAFE HARBOR STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE Study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; global unrest; and the continued impact of the COVID-19 pandemic. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2022, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.

CONTACTS

Investors
LifeSci Advisors 
Mike Moyer, Managing Director 
617.308.4306 
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media inquiries
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners
858.717.2310
646.942.5604
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.